Takeda Pharmaceutical unveiled a series of restructuring measures that will result in the loss of 2,800 jobs. The Japanese pharmaceutical company says it is moving to "better align the global workforce and consolidate site operations" after the integration of Nycomed, a Swiss company that Takeda acquired last year for 9.6 billion euros.
Chief Executive Officer Yasuchika Hasegawa notes that "while our combined operations complement rather than overlap in more than 70 countries, there will be a need to make adjustments across a number of sectors to ensure operational efficiency and flexible development." Takeda expects "the consolidation of a number of sites and functions, including the potential merger or liquidation of subsidiaries," mainly in Europe, and a reduction in the workforce in the United States.
But of the 2,800 jobs that will be cut by the end of fiscal 2015, 2,100 will be lost in Europe, 1,200 of them in Germany, and the rest will be eliminated overseas. The cuts will occur in research and development, commercial, operations and administrative sectors and will allow for net savings of approximately 130 billion yen ($1.7 billion).
January 19, 2012 – PharmaKronos
